Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Hepalink Pharma’s Shares Fall on Lower Profit

publication date: Jul 29, 2011
Shenzhen Hepalink Pharmaceutical, a company that makes APIs for the blood thinner heparin, said 2011 first-half results were hurt by higher costs and lower revenues. Hepalink reported first-half net income dropped 40% to 362 million RMB ($56.2 million) on revenues that fell 13% to 1.6 billion RMB ($249 million). Earnings per share were 44% lower at .45 RMB. Hepalink derives the majority of its revenues from ex-China sales of its heparin products. More details....

Stock Symbol: (SHE: 002399)

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital